Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 20, 2026, 6:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 708 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dry Eye Clear all
Completed Phase 1 Interventional

Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease

NCT05031806
View directory record Official record
Conditions
Dry Eye Disease
Interventions
iNexin™ (0.08% aCT1), iNexin™ (0.4% aCT1), iNexin™ (2.0% aCT1), Vehicle (eye drop formulation without aCT1)
Drug
Lead sponsor
Xequel Bio, Inc.
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Jul 20, 2026, 6:40 PM EDT
Recruiting No phase listed Observational

The Pathogenesis and Natural History of Sjogren's Disease

NCT01425892
View directory record Official record
Conditions
Sjogren's Syndrome, Salivary Gland, Pathogenesis
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
16 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Not applicable Interventional

Changes in Tear Osmolarity Over Time With Sustained Use of TheraTears

NCT02100787
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
TheraTears lubricating drops
Other
Lead sponsor
Jenkins Eye Care
Other
Eligibility
21 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Not applicable Interventional

Systane Complete Multi-symptom Relief

NCT05056155
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Systane Complete
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Kansas City, Missouri • Granville, Ohio • Powell, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 2 Interventional Results available

Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

NCT03333057
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
NOV03, Placebo
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
11
States / cities
Artesia, California • Newport Beach, California • Santa Ana, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Not applicable Interventional

Feasibility of Dynamic Muscle Stimulation + Radiofrequency for Improving Blink Quality in Subjects with Dry Eye Disease

NCT05945069
View directory record Official record
Conditions
Eyelid Diseases, Eyelid Movement Disorders, Dry Eye, Dry Eye Syndromes, Skin Laxity
Interventions
TriLift device
Device
Lead sponsor
Lumenis Be Ltd.
Industry
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 2 Interventional Results available

Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye

NCT01393132
View directory record Official record
Conditions
Dry Eye, Sjogren's Syndrome, Graft vs. Host Disease
Interventions
Thymosin Beta 4 eye drops, Vehicle Control
Drug
Lead sponsor
Michigan Cornea Consultants, PC
Other
Eligibility
18 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Jul 20, 2026, 6:40 PM EDT
Recruiting Phase 1 Interventional

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

NCT07041099
View directory record Official record
Conditions
Sjögren, Sjogren Disease, Sjogren's Syndrome
Interventions
CLN-978
Drug
Lead sponsor
Cullinan Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Orlando, Florida • Memphis, Tennessee • Plano, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)

NCT02121301
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Low Dose 0.155µg/mL SkQ1 ophthalmic solution, High Dose 1.55µg/mL SkQ1 ophthalmic solution, Placebo (Vehicle) opthalmic solution
Drug
Lead sponsor
Mitotech, SA
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2020 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Digital Device Users Who Are Treated With Systane Hydration PF

NCT04837807
View directory record Official record
Conditions
Dry Eye
Interventions
Systane Hydration PF
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Jul 20, 2026, 6:40 PM EDT
Terminated Not applicable Interventional Results available

Management of Signs and Symptoms Associated With Dry Eye Disease

NCT04015219
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Self retained cryopreserved amniotic membrane, lifitegrast ophthalmic solution
Device · Other
Lead sponsor
BioTissue Holdings, Inc
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Jul 20, 2026, 6:40 PM EDT
Withdrawn Not applicable Interventional

Omega 3 Supplementation and Ocular Surface Disease in Glaucoma

NCT01630551
View directory record Official record
Conditions
Ocular Surface Disease
Interventions
Fishoil supplement, Olive Oil
Dietary Supplement
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Jul 20, 2026, 6:40 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Single Center, Prospective, Randomized, Controlled, Non-significant Risk

NCT03286166
View directory record Official record
Conditions
Dry Eye
Interventions
Not listed
Lead sponsor
Toyos Clinic
Other
Eligibility
22 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Jul 20, 2026, 6:40 PM EDT
Active, not recruiting Phase 2 Interventional

A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

NCT05839041
View directory record Official record
Conditions
Geographic Atrophy of the Macula, Macular Degeneration
Interventions
AVD-104, Avacincaptad
Drug
Lead sponsor
Aviceda Therapeutics, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
56
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Patients With Blepharitis and Facial Rosacea

NCT00560703
View directory record Official record
Conditions
Blepharitis, Meibomianitis, Dry Eye
Interventions
COL-101 (doxycycline, USP) capsules, placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Little Rock, Arkansas • Naples, Florida • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of TOP1630 for Dry Eye Syndrome

NCT03088605
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
TOP1630 Ophthalmic Solution, Placebo to TOP1630 Ophthalmic Solution
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome

NCT03100942
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Lanraplenib, Filgotinib, Tirabrutinib, Lanraplenib placebo, Filgotinib placebo, Tirabrutinib placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
34
States / cities
Mesa, Arizona • Phoenix, Arizona • Covina, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Jul 20, 2026, 6:40 PM EDT
Recruiting Not applicable Interventional

BriTer Eyez Moisture Vue™ On-Demand Disposable Moisture Chamber

NCT07430735
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
BriTer Eyez Moisture Vue™ On Demand Disposable Moisture Chamber
Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)

NCT05082974
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline 0.6mg/ml) nasal spray, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Vance Thompson Vision ND
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
West Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 4 Interventional Results available

Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy

NCT02121847
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
cyclosporine 0.05% ophthalmic emulsion, carboxymethylcellulose-based lubricant eye drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Jul 20, 2026, 6:40 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy

NCT06018558
View directory record Official record
Conditions
Geographic Atrophy
Interventions
OCU410
Genetic
Lead sponsor
Ocugen
Industry
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
12
States / cities
Phoenix, Arizona • Coral Springs, Florida • Carmel, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Jul 20, 2026, 6:40 PM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of Raptiva to Treat Sjogren's Syndrome

NCT00344448
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Raptiva
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 20, 2015 · Synced Jul 20, 2026, 6:40 PM EDT
Recruiting Phase 4 Interventional

Quality of Life in Presbyopic Patients Who Are Treated With Qlosi

NCT07113210
View directory record Official record
Conditions
Presbyopia, Glasses, Dry Eye
Interventions
pilocarpine HCL ophthalmic solution
Drug
Lead sponsor
Southern College of Optometry
Other
Eligibility
45 Years to 64 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Medina, Minnesota • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Jul 20, 2026, 6:40 PM EDT
Active, not recruiting Not applicable Interventional

PRIMA US-Feasibility Study in Atrophic Dry AMD

NCT03392324
View directory record Official record
Conditions
Dry Age-related Macular Degeneration
Interventions
PRIMA
Device
Lead sponsor
Science Corporation
Industry
Eligibility
60 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
3
States / cities
Palo Alto, California • Miami, Florida • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 20, 2026, 6:40 PM EDT